Tolterodine is used to relieve urinary difficulties, including frequent urination and inability to control urination. Tolterodine belongs to a class of medications called antimuscarinics. It acts by preventing bladder contraction. It is sold under the trade names Detrol and Detrusitol. DETROL Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

The chemical name of tolterodine is (R)-N,N-diizopropyl-3-
(2-hydroxy-5-methylphenyl)- -3-phenylpropamine. It is delivered in pharmaceutical form as a tartrate. The empiric formula is C₂₆H₃₇NO₇ and the structural formula is represented below:

Synthesis of tolterodine tartrate was firstly revealed in patent EP 0325571 B1 published in 1989. It describes synthesis consisted of seven steps, which starts from p-cresol and trans-cinnamic acid. There is also a modification of first method. This alternative route contains eight synthetic steps. We found that patent description lacks a lot of very important information e.g. purity of intermediates or methods of their purification. It was not mentioned if products were obtained in crystalline, amorphous or oil form.

We decided to investigate both of synthetic routes to gain missing information and to evaluate their usefulness for application in industrial scale.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/15255 must be provided.

1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
2. Determination of organic volatile impurities in Nepafenac by GC method
3. Application of the new data processing method for photodiode array detector in the analysis of drug substances
4. Improved manufacturing process of bosentan monohydrate.
5. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
6. Evaluation of potential genotoxic impurities in prasugrel intermediate by HPLC chromatography
7. Simultaneous CE determination of counterion and possible impurity from synthetic route in pharmaceutical substance prasugrel hydrochloride.
8. Assessment of selected synthesis of bosentan towards elimination of known impurities.
9. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
10. Efficient preparation of a key intermediate in the exemestane synthesis
11. Determination of reaction progress in synthesis of EE-3 by NMR technique
12. Opimisation of preparation of TZ-6
13. HPLC method as an analitycal control of synthesis and determination of TZ-S
14. Investigation of unknown impurity of TD-S by HPLC-MS
15. Exploration of sugar-based inhibitors of glycolysis to target brain tumors
16. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
17. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
18. Synthesis of selected ¹⁴C radiolabelled compounds in recent investigations of new analytical method applied in accelerated drug development (EUMAPP).
19. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
20. Searching for lead molecules as potential new CNS agents in the serotonin 5-HT₆ screening assay
21. QUINONES AND HYDROQUINONES SEPARATION AND DETERMINATION BY HPLC CHROMATOGRAPHY
22. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
23. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
24. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC^®) SYNTHESIS.